LY333531 [ruboxistaurin] treatment of symptomatic peripheral neuropathy in patients with diabetes

Trial Profile

LY333531 [ruboxistaurin] treatment of symptomatic peripheral neuropathy in patients with diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Ruboxistaurin (Primary)
  • Indications Diabetic neuropathies
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 23 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top